The purpose of this study is to find out what effects (good and bad) the study medications (insulin or Empagliflozin) have on adults with mild memory impairment or early Alzheimer's disease who are clinically prescribed an anti-amyloid therapy compared to placebo.
Fluent in English
Diagnosis of mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease via previously documented clinical assessment
Amyloid positive by PET or cerebrospinal fluid criteria
Stable medical condition for 3 months prior to screening visit
A diagnosis of dementia other than Alzheimer's disease
History of a clinically significant stroke, history of transient ischemic attack within 12 months, or any history of seizures
Current evidence or history in past two years of head injury with loss of consciousness, any major psychiatric disorder including psychosis, unstable major depressive disorder, bipolar disorder
Diabetes (type I or type II) insulin dependent and non-insulin dependent diabetes mellitus